Retina

The current prior authorization process required for anti-VEGF medications leads to treatment delays, increased health care costs due to administrative burdens and potentially worse visual outcomes.

Genentech is set to reintroduce Susvimo for patients with wet age-related macular degeneration nearly 2 years after it voluntarily recalled the ocular implant, according to a press release.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Shankar Ramaswamy, MD, of Kriya Therapeutics highlights the company’s gene therapy programs for geographic atrophy and thyroid eye disease.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, of Sierra Eye Associates in Nevada, presents 3-month data on AVD-104 for geographic atrophy.

Alcon completed the acquisition of Belkin Vision, including its direct selective laser trabeculoplasty technology, according to a press release.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Michael Singer, MD, of the University of Texas Health Science Center, discusses 36-month data investigating Yutiq for chronic noninfectious uveitis.

The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on the marketing authorization application for pegcetacoplan for the treatment of geographic atrophy.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Russ Trenary, president and CEO of Outlook Therapeutics, discusses the development of ONS-5010.

The FDA granted 510(k) clearance to Alcon’s Unity combined vitreoretinal cataract system and stand-alone cataract system, according to a press release.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Lori Taylor of Annexon Biosciences previews data on ANX007 for the treatment of geographic atrophy.